A promising novel therapy for the treatment of prostate cancer is being developed by researchers at Sunnybrook Research Institute (SRI). The treatment may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.
The new treatment—magnetic resonance imaging (MRI)-guided transurethral ultrasound—uses heat from focused ultrasound to treat cancer in the prostate gland precisely while sparing the delicate noncancerous tissues around the prostate essential for healthy urinary, bowel and sexual function.
Sunnybrook researchers Dr. Michael Bronskill and Dr. Rajiv Chopra have licensed their innovation and formed Profound Medical Inc., which will develop the technology for clinical use.
Unlike surgical removal of the prostate, the treatment is minimally invasive and could be performed without a lengthy hospital stay. In preclinical studies, treatment takes less than 30 minutes.
The therapy, on which clinicians at Sunnybrook will conduct preliminary testing in preparation for a clinical trial, could help limit the number of men living with the common, debilitating and often permanent side effects of surgery and radiation treatments currently used.
More of these invasive therapies are being performed now because improved awareness among younger men has converged with better clinical detection tools.
The therapy involves two different and naturally incompatible technologies, ultrasound and MRI, which Bronskill and Chopra spent 10 years making compatible.
"The prostate cancer site is a natural for this technology because it''s surrounded by structures you want to spare,” the expert added.
Dr. Laurence Klotz, chief of urology at Sunnybrook Health Sciences Centre, and a professor at the University of Toronto, says that a noninvasive therapy for early, localized prostate cancer could improve the quality of life of hundreds of thousands of men.